Veloxis Pharma Inc.

Veloxis Pharma Inc. is a fully integrated specialty pharmaceutical company focused on improving the lives of transplant patients. Headquartered in Cary, North Carolina, USA, Veloxis was founded in 2002 and became a wholly owned, indirect subsidiary of Asahi Kasei in March 2020 through an acquisition valued at $1.36 billion. As part of Asahi Kasei, Veloxis is part of a global network with over 40,000 employees worldwide.

The company specializes in the global development and commercialization of medications for transplant patients and those with serious related diseases. Its primary product is ENVARSUS XR (tacrolimus extended-release tablets), a once-daily immunosuppressant that uses proprietary MeltDose® technology for the prophylaxis of organ rejection in kidney transplant patients. Veloxis also has a product pipeline that includes VEL-101, an investigational immunosuppressant for kidney transplant recipients, which has received FDA Fast Track designation.

Veloxis Pharma Inc. appears to be an operating company that actively defends and asserts its intellectual property. The company has one tracked case, where it is listed as a plaintiff. This case, Veloxis Pharma Inc. v. Alkem Laboratories Ltd., was filed in 2024 in the U.S. District Court for the District of Delaware. The company has previously been involved in other patent infringement litigation in the District of Delaware, specifically Hatch-Waxman patent disputes concerning generic versions of its ENVARSUS XR product. In a notable case, Veloxis Pharmaceuticals, Inc. v. Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd., Veloxis secured a consent judgment and permanent injunction against generic entry of ENVARSUS XR tacrolimus until patent expiry.